Floatz logo

9-valent human papillomavirus recombinant vaccine

Anal Intraepithelial Neoplasia

Xiamen UniversityvaccinePhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Anal Intraepithelial Neoplasia cohort.

Asset / SponsorPhaseRating
9vhpv vaccine
Merck Sharp & Dohme LLC
Phase 3BB
ACETIC ACID, TRICHLORO-
University Hospital, Essen
N/AD

Same molecule, other indications

9-valent human papillomavirus recombinant vaccine is also rated in:

penile cancerDormant
B
Indicative ·
60 / 100
View asset →
anogenital human papillomavirus infectionDormant
B
Indicative ·
60 / 100
View asset →
prostate intraepithelial neoplasiaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →